About Us

About Cytovation

Cytovation AS is a privately held biotech company based in Bergen, Norway and specialising in the development of immunotherapy for solid tumours.

Who we are

 

Cytovation was founded in 2001 with strong ties to leading scientific research groups at Haukeland University Hospital and the University of Bergen. The company is currently developing CyPep-O1 for the treatment of multiple cancer indications.

The company’s founders are well-renowned experts in their fields and the authors of an extensive number of scientific publications.

Board of Directors


Per Eystein Lønning, MD  PhD

Per Eystein Lønning, MD PhD

Chairman

Per Eystein Lønning, MD and PhD, is professor and senior consultant in oncology.

Per Eystein Lønning, MD and PhD, is professor and senior consultant in oncology.

Professor Rolf Bjerkvig, PhD

Professor Rolf Bjerkvig, PhD

Board member

Dr Bjerkvig is Professor in Cell Biology at the University of Bergen, Norway.

Dr Bjerkvig is Professor in Cell Biology at the University of Bergen, Norway.

Kristin Pundsnes

Kristin Pundsnes

Board Member

Kristin is currently Chief Financial Officer at Haukeland University Hospital, Bergen.

Kristin is currently Chief Financial Officer at Haukeland University Hospital, Bergen.

Leadership Team


Kjell-Inge Arnevig

Kjell-Inge Arnevig

Chief Executive officer

Kjell-Inge Arnevig has more than 25 years’ experience in senior and executive positions.

Kjell-Inge Arnevig has more than 25 years’ experience in senior and executive positions.

Lars Prestegarden MD, PhD

Lars Prestegarden MD, PhD

Chief scientific officer

Dr Prestegarden is a co-founder of Cytovation and a board certified specialist in dermatology.

Dr Prestegarden is a co-founder of Cytovation and a board certified specialist in dermatology.